Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TRIV-02
- Development stage
- Preclinical
- Lead developer
- Genovyn
- Modality
- Small Molecules
01
Overview
TRIV-02 is a preclinical-stage small molecule combination therapy being developed by Genovyn (also referred to as Genvoyn) for the treatment of Triple-Negative Breast Cancer (TNBC). As part of Genovyn's Tripsovyn program, TRIV-02 is designed as a multi-target combination therapy that operates independently of traditional hormone (estrogen and progesterone) and HER2 receptor pathways. The program has completed target and lead identification and is currently undergoing in vitro, in vivo, and safety toxicology studies to support future IND enablement.
Beyond the preview
Go deeper on TRIV-02.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TRIV-02.